Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Subscribe To Our Newsletter & Stay Updated